CN119546343A - 细胞因子融合蛋白与cd8抗原结合分子的组合 - Google Patents

细胞因子融合蛋白与cd8抗原结合分子的组合 Download PDF

Info

Publication number
CN119546343A
CN119546343A CN202380050634.5A CN202380050634A CN119546343A CN 119546343 A CN119546343 A CN 119546343A CN 202380050634 A CN202380050634 A CN 202380050634A CN 119546343 A CN119546343 A CN 119546343A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
cdr
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380050634.5A
Other languages
English (en)
Chinese (zh)
Inventor
I·朱勒蒂
瑞妮·L·葛蕾尔
杨翊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asher Biotherapy Co
Original Assignee
Asher Biotherapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asher Biotherapy Co filed Critical Asher Biotherapy Co
Publication of CN119546343A publication Critical patent/CN119546343A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202380050634.5A 2022-04-27 2023-04-26 细胞因子融合蛋白与cd8抗原结合分子的组合 Pending CN119546343A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263335697P 2022-04-27 2022-04-27
US63/335,697 2022-04-27
PCT/US2023/019989 WO2023212056A2 (en) 2022-04-27 2023-04-26 Combination of cytokine fusion proteins with cd8 antigen binding molecules

Publications (1)

Publication Number Publication Date
CN119546343A true CN119546343A (zh) 2025-02-28

Family

ID=88519563

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380050634.5A Pending CN119546343A (zh) 2022-04-27 2023-04-26 细胞因子融合蛋白与cd8抗原结合分子的组合

Country Status (9)

Country Link
US (1) US20250339519A1 (cg-RX-API-DMAC7.html)
EP (1) EP4514397A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025515470A (cg-RX-API-DMAC7.html)
KR (1) KR20250027597A (cg-RX-API-DMAC7.html)
CN (1) CN119546343A (cg-RX-API-DMAC7.html)
AU (1) AU2023259161A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250301A1 (cg-RX-API-DMAC7.html)
TW (1) TW202400664A (cg-RX-API-DMAC7.html)
WO (1) WO2023212056A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
WO2026162740A1 (en) * 2025-01-31 2026-08-06 Astrazeneca Ab Cd8-binding cytokine engager combination therapies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200306301A1 (en) * 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
JP2020533971A (ja) * 2017-08-28 2020-11-26 アルター・バイオサイエンス・コーポレーション Il−15をベースとするil−7及びil−21への融合物
JP7778571B2 (ja) * 2019-06-05 2025-12-02 アッシャー バイオセラピューティクス, インコーポレイテッド 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体
EP4175979A2 (en) * 2020-07-02 2023-05-10 Inhibrx, Inc. Polypeptides comprising modified il-2 polypeptides and uses thereof
KR20230086765A (ko) * 2020-10-13 2023-06-15 얀센 바이오테크 인코포레이티드 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
KR20230112632A (ko) * 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
WO2022245500A1 (en) * 2021-05-19 2022-11-24 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs

Also Published As

Publication number Publication date
CA3250301A1 (en) 2023-11-02
JP2025515470A (ja) 2025-05-15
KR20250027597A (ko) 2025-02-26
EP4514397A2 (en) 2025-03-05
AU2023259161A1 (en) 2024-11-28
TW202400664A (zh) 2024-01-01
WO2023212056A2 (en) 2023-11-02
US20250339519A1 (en) 2025-11-06
WO2023212056A3 (en) 2023-12-07
EP4514397A4 (en) 2026-05-20

Similar Documents

Publication Publication Date Title
JP7847584B2 (ja) 免疫細胞機能をモジュレートするためのcd8抗原結合分子を有する融合物
JP7148539B2 (ja) 免疫抱合体
US11591401B2 (en) Anti-CD28 compositions
JP7853916B2 (ja) 免疫複合体
KR20210134725A (ko) Enpp3과 cd3에 결합하는 이종이량체 항체
KR20210091710A (ko) PD-1 표적화 IL-15/IL-15Rα Fc 융합 단백질 및 병용요법에서의 이의 용도
US12122827B2 (en) IL-21 polypeptides and targeted constructs
US20240010695A1 (en) Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function
US20250339519A1 (en) Combination of cytokine fusion proteins with cd8 antigen binding molecules
US20260098090A1 (en) Fusions with cd8 antigen binding molecules for treating chronic viral infection
CN116829577A (zh) 用于调节免疫细胞功能的突变型白介素-10多肽与抗原结合分子的融合物
HK40129535A (en) Il-21 polypeptides and targeted constructs
CN116997362A (zh) 含调节免疫细胞功能的cd8抗原结合分子的融合物
EA052306B1 (ru) Слитые белки и их применение, полинуклеотид, кодирующий их, вектор экспрессии, выделенная клетка-хозяин, способ получения слитого белка, фармацевтическая композиция, способ лечения рака, способ размножения т-клеток ex vivo
HK40123337A (en) Immunoconjugates
EA051898B1 (ru) Полипептиды il-21 и нацеленные конструкции

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination